Allt inom MAR

All Primary and Secondary endpoints met in Nanexa’s Phase I study of the one-month GLP-1 depot NEX-22

Nanexa AB today announce positive results in the company’s Phase I study for NEX-22, long acting GLP-1, in type 2 diabetes. The study evaluates a once-monthly depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system.

Nanexa publishes interim report for January-June 2024

NEX-22 clinical trial initiated and proceeding with dose escalation as planned